Short answer
BridgeBio Pharma, Inc. (BBIO) filed an 8-K current report with the SEC on August 31, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Agreement with U.S. government targets affordability and access for BridgeBio’s future medicines.
BridgeBio Pharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Agreement with U.S. government targets affordability and access for BridgeBio’s future medicines
- Pricing commitment expected to exclude medicines approved exclusively for orphan indications
- Medicaid access expansion for Attruby planned through the GENEROUS Model
- Potential protection from future pricing mandates, subject to government implementation and interpretation
- Exhibit 99.1 contains the agreement’s substantive terms and expected market impact
Item EX-99.1 · Exhibit EX-99.1
- Voluntary U.S. agreement expands Medicaid access to Attruby through the GENEROUS Model
- Attruby remains available through Medicare Part D without future pricing mandates
- Confidential terms create uncertainty around potential revenue and margin impact
- ForgingBridges copay assistance remains unchanged, potentially reducing qualifying patients’ costs to $0 monthly
- Three additional medicines under FDA review, with BBP-418 PDUFA date November 27, 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other BridgeBio Pharma, Inc. 8-K filings
Get the next BBIO 8-K as it lands
Follow BBIO for push alerts, or ask the research agent what this filing means.